These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35902386)

  • 1. Registry-based randomised clinical trials: a remedy for evidence-based diabetes care?
    Eriksson JW; Eliasson B; Bennet L; Sundström J
    Diabetologia; 2022 Oct; 65(10):1575-1586. PubMed ID: 35902386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining key design elements of registry-based randomised controlled trials: a scoping review.
    Karanatsios B; Prang KH; Verbunt E; Yeung JM; Kelaher M; Gibbs P
    Trials; 2020 Jun; 21(1):552. PubMed ID: 32571382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A registry-based randomised trial comparing an SGLT2 inhibitor and metformin as standard treatment of early stage type 2 diabetes (SMARTEST): Rationale, design and protocol.
    Sundström J; Kristófi R; Östlund O; Bennet L; Eliasson B; Jansson S; Leksell J; Almby K; Lundqvist M; Eriksson JW;
    J Diabetes Complications; 2021 Oct; 35(10):107996. PubMed ID: 34389234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Nothing to lose and the possibility of gaining": a qualitative study on the feasibility and acceptability of registry-based randomised controlled trials among cancer patients and clinicians.
    Prang KH; Karanatsios B; Zhang A; Verbunt E; Wong HL; Wong V; Gately L; Tran B; Gibbs P; Kelaher M
    Trials; 2023 Feb; 24(1):92. PubMed ID: 36747274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
    Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
    BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health care registers can be instrumental for endpoint capture in clinical diabetes trials: example of microvascular complications in Swedish patients with type 2 diabetes.
    Lundqvist MH; Patsoukaki V; Jansson S; Norman H; Granstam E; Svensson MK; Sundström J; Eliasson B; Eriksson JW
    Diab Vasc Dis Res; 2023; 20(3):14791641231179878. PubMed ID: 37318227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Registry randomised trials: a methodological perspective.
    Doherty DA; Tong SYC; Reilly J; Shrapnel J; McDonald S; Ahern S; Harris I; Tam CS; Brennan AL; Hodgson C; Wilcox L; Balagurunathan A; Butcher BE; Reid CM
    BMJ Open; 2023 Mar; 13(3):e068057. PubMed ID: 36858472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paper II: thematic framework analysis of registry-based randomized controlled trials provided insights for designing trial ready registries.
    Krause KR; Tay J; Douglas WA; Sammy A; Baba A; Goren K; Thombs BD; Howie AH; Oskoui M; Frøbert O; Trakadis Y; Little J; Potter BK; Butcher NJ; Offringa M
    J Clin Epidemiol; 2023 Jul; 159():330-343. PubMed ID: 37146660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical registries data quality attributes to support registry-based randomised controlled trials: A scoping review.
    Prang KH; Karanatsios B; Verbunt E; Wong HL; Yeung J; Kelaher M; Gibbs P
    Contemp Clin Trials; 2022 Aug; 119():106843. PubMed ID: 35792338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project.
    Arnold SV; Inzucchi SE; Tang F; McGuire DK; Mehta SN; Maddox TM; Goyal A; Sperling LS; Einhorn D; Wong ND; Khunti K; Lam CS; Kosiborod M
    Eur J Prev Cardiol; 2017 Oct; 24(15):1637-1645. PubMed ID: 28870145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
    Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
    Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.